Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
Kintara Therapeutics (Nasdaq: KTRA) announced its presentation at the 2nd Annual Glioblastoma Drug Development Virtual Summit on December 10, 2020, at 11:45 A.M. EST. Dr. John de Groot and Dr. James Perry will discuss VAL-083, a first-in-class bifunctional alkylating agent showing promise against both MGMT unmethylated and methylated glioblastoma. Kintara is committed to developing novel cancer therapies, including VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer, addressing significant unmet medical needs.
- None.
- None.
SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10, 2020 at 11:45 A.M. EST.
Dr. John de Groot, Professor, Department of Neuro-Oncology, MD Anderson Cancer Center, and Dr. James Perry, Professor of Neurology, at the University of Toronto Temerty Sunnybrook Research Institute will present a talk titled "Kintara's VAL-083: A First-in-Class Bifunctional Alkylating Agent with Promising Activity in MGMT Promoter- Unmethylated & Methylated Glioblastoma."
Drs. de Groot and Perry are the Principal Investigators of Kintara's arm of the Global Coalition for Adaptive Research (GCAR) Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study.
ABOUT GLOBAL COALITION FOR ADAPTIVE RESEARCH
GCAR is a 501(c)(3) nonprofit organization uniting physicians, clinical researchers, advocacy and philanthropic organizations, biopharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases by serving as sponsor of innovative and complex trials including master protocols and platform trials. GCAR is the sponsor of GBM AGILE, an adaptive platform trial for patients with GBM – the most common and deadliest of malignant primary brain tumors.
To learn more about GCAR, visit www.gcaresearch.org and follow us: @GCAResearch and www.facebook.com/GCAResearch.
ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS:
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit-301185678.html
SOURCE Kintara Therapeutics
FAQ
When is Kintara's presentation at the Glioblastoma Drug Development Summit?
Who will present on Kintara's VAL-083 at the summit?
What is VAL-083?
What are the main focuses of Kintara Therapeutics?
What role does the Global Coalition for Adaptive Research play in Kintara's studies?
